Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Traws Pharma ( (TRAW) ) has shared an update.
On August 18, 2025, Traws Pharma announced approval from the Human Research Ethics Committee to proceed with Phase 2 studies for ratutrelvir, a ritonavir-free COVID-19 treatment. The trials aim to evaluate its safety and efficacy compared to PAXLOVID® and in PAXLOVID®-ineligible patients. Results are expected by the end of 2025, potentially positioning ratutrelvir as a new standard of care for COVID-19, especially for vulnerable populations.
The most recent analyst rating on (TRAW) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases, including COVID-19, Long COVID, bird flu, and seasonal influenza. The company integrates antiviral drug development, medical intelligence, and regulatory strategy to address real-world challenges, with products like ratutrelvir and tivoxavir marboxil in development.
Average Trading Volume: 1,184,902
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.67M
Learn more about TRAW stock on TipRanks’ Stock Analysis page.